Anver Kuliev
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Anver Kuliev has a total of 284 co-authors. Here are the top co-authors by number of shared publications:
Yury Verlinsky
Reproductive Genetics Institute, Chicago, IL, USA
57 shared publicationsSvetlana Rechitsky
Reproductive Genetic Innovations, Northbrook, Illinois, USA
45 shared publicationsOleg Verlinsky
26 shared publicationsY Verlinsky
24 shared publicationsY. Verlinsky
22 shared publicationsS Rechitsky
Reproductive Genetics Institute, Chicago, IL, USA
20 shared publications
Latest Publications
- 26 January 2026
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 52 (6) , 105498
Report of the PGDIS Task Group on the status of PGT-A
- 26 January 2026
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 52 (6) , 105498
Report of the PGDIS Task Group on the status of PGT-A
- Open Access
- 6 November 2018
- Published by MedCrave Group Kft. in Hematology & Transfusion International Journal
- Vol. 6 (6)
Preimplantation genetic testing for inherited immunodeficiency
Preimplantation genetic testing (PGT) has become a practical tool for at risk couples to avoid affected pregnancies and have a healthy progeny free from genetic and chromosomal disorders. PGT is also an option for stem cell transplantation treatment through combining PGT with preimplantation HLA typing for couples with children affected by congenital disorders, for whom no other alternative therapies are available, such as for congenital immunodeficiency. We present here our experience of 135 PGT cycles performed for 74 couples at risk for producing offspring with 18 different congenital immunodeficiencies, resulting in birth of 54 healthy children free from inherited immunodeficiency, which is one of the world’s largest PGT series for immunodeficiency.
- 6 November 2018
- Published by MedCrave Group Kft. in Hematology & Transfusion International Journal
- Vol. 6 (6)
Open AccessPreimplantation genetic testing for inherited immunodeficiency
Preimplantation genetic testing (PGT) has become a practical tool for at risk couples to avoid affected pregnancies and have a healthy progeny free from genetic and chromosomal disorders. PGT is also an option for stem cell transplantation treatment through combining PGT with preimplantation HLA typing for couples with children affected by congenital disorders, for whom no other alternative therapies are available, such as for congenital immunodeficiency. We present here our experience of 135 PGT cycles performed for 74 couples at risk for producing offspring with 18 different congenital immunodeficiencies, resulting in birth of 54 healthy children free from inherited immunodeficiency, which is one of the world’s largest PGT series for immunodeficiency.
- 1 March 2018
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 36, e38-e39
Impact of application of next generation technologies on the outcome of preimplantation genetic testing for structural rearrangements (PGT-SR)
- 1 March 2018
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 36, e38-e39
Impact of application of next generation technologies on the outcome of preimplantation genetic testing for structural rearrangements (PGT-SR)
- Open Access
- 1 January 2018
- Published by Open Access Text Pvt, Ltd. in Clinical Obstetrics, Gynecology and Reproductive Medicine
- Vol. 4 (4)
Preimplantation Genetic Testing (PGT) for breast cancer
- 1 January 2018
- Published by Open Access Text Pvt, Ltd. in Clinical Obstetrics, Gynecology and Reproductive Medicine
- Vol. 4 (4)
Open AccessPreimplantation Genetic Testing (PGT) for breast cancer
- 8 November 2017
- Published by Taylor & Francis in Expert Review of Molecular Diagnostics
- Vol. 17 (12) , 1071-1088
Preimplantation genetic testing: current challenges and future prospects
Introduction: Preimplantation genetic testing (PGT) is now a widely applied procedure in genetic practices and ART, with more than one third of ART Centers in US already utilizing PGT technology. Its indications have also been significantly extended to include common late-onset disorders and non-genetic conditions, such as testing for HLA match. Areas covered: This is a critical review of the developments in PGT, with emphasis on their outstanding limitations and directions for the future research and practice in the area of PGT. Expert commentary: The application of the new higher resolution PGT technologies has led to the identification of genetic variations, the biological and clinical importance of which is not sufficiently understood. It is obvious that the current selection process of embryos with the highest developmental potential requires a further improvement, as significant proportion of transferred euploid embryos still fail to result in an ongoing clinical pregnancy. More research will be needed to upgrade PGT for different conditions into a single universal test in the same biopsy material. To avoid a potential damage of embryo biopsy procedures, one of the important challenges will be the development of non-invasive approaches to PGT.
- 8 November 2017
- Published by Taylor & Francis in Expert Review of Molecular Diagnostics
- Vol. 17 (12) , 1071-1088
Preimplantation genetic testing: current challenges and future prospects
Introduction: Preimplantation genetic testing (PGT) is now a widely applied procedure in genetic practices and ART, with more than one third of ART Centers in US already utilizing PGT technology. Its indications have also been significantly extended to include common late-onset disorders and non-genetic conditions, such as testing for HLA match. Areas covered: This is a critical review of the developments in PGT, with emphasis on their outstanding limitations and directions for the future research and practice in the area of PGT. Expert commentary: The application of the new higher resolution PGT technologies has led to the identification of genetic variations, the biological and clinical importance of which is not sufficiently understood. It is obvious that the current selection process of embryos with the highest developmental potential requires a further improvement, as significant proportion of transferred euploid embryos still fail to result in an ongoing clinical pregnancy. More research will be needed to upgrade PGT for different conditions into a single universal test in the same biopsy material. To avoid a potential damage of embryo biopsy procedures, one of the important challenges will be the development of non-invasive approaches to PGT.
- 1 September 2017
- Published by Elsevier in Fertility and Sterility
- Vol. 108 (3) , e271
Prevalence of segmental chromosome abnormalities in next generation seqeuencing (NGS) based 24-chromosome preimplantation aneuploidy testing (PGD-A)
- 1 September 2017
- Published by Elsevier in Fertility and Sterility
- Vol. 108 (3) , e271
Prevalence of segmental chromosome abnormalities in next generation seqeuencing (NGS) based 24-chromosome preimplantation aneuploidy testing (PGD-A)
- 1 September 2017
- Published by Elsevier in Fertility and Sterility
- Vol. 108 (3) , e268-e269
Preimplantation genetic diagnosis (PGD) for borderline indications including human leukocyte antigens (HLA) matching, cancer predisposition, cardiac disease and their proportion in overall PGD cases for single gene disorders
- 1 September 2017
- Published by Elsevier in Fertility and Sterility
- Vol. 108 (3) , e268-e269
Preimplantation genetic diagnosis (PGD) for borderline indications including human leukocyte antigens (HLA) matching, cancer predisposition, cardiac disease and their proportion in overall PGD cases for single gene disorders
- 1 September 2017
- Published by Elsevier in Fertility and Sterility
- Vol. 108 (3) , e272
Relationship between embryo developmental competence and mitochondrial DNA levels
- 1 September 2017
- Published by Elsevier in Fertility and Sterility
- Vol. 108 (3) , e272
Relationship between embryo developmental competence and mitochondrial DNA levels
- Open Access
- 27 March 2017
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 52 (9) , 1249-1252
First experience of hematopoietic stem cell transplantation treatment of Shwachman–Diamond syndrome using unaffected HLA–matched sibling donor produced through preimplantation HLA typing
The only proven cure for Shwachman-Diamond syndrome (SDS) bone marrow failure is allogeneic hematopoietic stem cell transplantation (HSCT). However HSCT with donors other than HLA-identical siblings is associated with high mortality and unfavorable prognosis. This paper presents the first experience of HSCT treatment of SDS using an unaffected HLA-identical sibling produced through preimplantation genetic diagnosis (PGD). The patient was a 6-year-old blood transfusion-dependent SDS baby girl with secondary myelodysplastic syndrome, for whom no HLA-identical donor was available. As a result of PGD, two unaffected HLA matched embryos were identified; one of them was randomly selected for transfer, resulting in a clinical pregnancy and birth of an apparently healthy child. The patient underwent allogeneic transplantation of cord blood hematopoietic stem cells, together with bone marrow from this sibling, resulting in complete hemopoietic recovery. The patient was no longer transfusion-dependent and had normal blood values 160 days after transplantation.
- 27 March 2017
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 52 (9) , 1249-1252
Open AccessFirst experience of hematopoietic stem cell transplantation treatment of Shwachman–Diamond syndrome using unaffected HLA–matched sibling donor produced through preimplantation HLA typing
The only proven cure for Shwachman-Diamond syndrome (SDS) bone marrow failure is allogeneic hematopoietic stem cell transplantation (HSCT). However HSCT with donors other than HLA-identical siblings is associated with high mortality and unfavorable prognosis. This paper presents the first experience of HSCT treatment of SDS using an unaffected HLA-identical sibling produced through preimplantation genetic diagnosis (PGD). The patient was a 6-year-old blood transfusion-dependent SDS baby girl with secondary myelodysplastic syndrome, for whom no HLA-identical donor was available. As a result of PGD, two unaffected HLA matched embryos were identified; one of them was randomly selected for transfer, resulting in a clinical pregnancy and birth of an apparently healthy child. The patient underwent allogeneic transplantation of cord blood hematopoietic stem cells, together with bone marrow from this sibling, resulting in complete hemopoietic recovery. The patient was no longer transfusion-dependent and had normal blood values 160 days after transplantation.
- 15 November 2016
- Published by Wiley
- p. 1-21
Preimplantation Diagnosis
Preimplantation diagnosis is testing for a causative gene before pregnancy, allowing the preselection of unaffected embryos before implantation into the uterus. It has currently become an alternative to prenatal diagnosis, providing an option for at‐risk couples to have unaffected children of their own without facing the risk of a pregnancy termination after prenatal diagnosis. Preimplantation diagnosis is also extended to late‐onset common disorders with genetic predisposition, such as cancer and heart disease, for which no preclinical diagnosis and effective preventive management exists. The other nontraditional application of preimplantation diagnosis is preimplantation HLA (human leukocyte antigen) typing to improve the access to the HLA‐identical stem cell transplantation, and this will contribute to the development of the cellular therapy for genetic and acquired disorders. However, the major current application of preimplantation genetic testing is detection and avoidance of aneuploid embryos, based on the currently used next‐generation technologies for 24‐chromosome aneuploidy testing, as the practical means in assisted reproduction technology (ART) to improve the in vitro fertilisation (IVF) effectiveness and general standards of ART. Key Concepts: PGD is no longer a research tool, but the established procedure in the genetic practices and ART. PGD not only avoids the birth of affected offspring but, most importantly, also ensures an unaffected pregnancy from the onset. Indications for PGD have currently been extended from the traditional ones, which are similar to prenatal diagnosis, to those that are not acceptable for prenatal diagnosis, such as late‐onset common disorders or identification of HLA match for stem cell transplantation. The majority of PGD is still performed for aneuploidy testing, as a tool to improve the efficiency of IVF. One of the most recent changes in PGD procedure in the last few years is shifting from blastomere biopsy to blastocyst sampling and vitrification, followed by the frozen transfer of tested embryos. The other important development in PGD is a shift of genetic testing from FISH testing for a few chromosomes most commonly involved in trisomies to the next‐generation technologies for 24‐chromosome aneuploidy testing. The number of different genetic conditions tested by PGD at the present time is over 400 and can be done not only for inherited conditions but also for those determined by de novo mutations. PGD for single‐gene disorders became extremely accurate and reliable, with as high as 99.5% accuracy in our PGD experience, which is the world's largest PGD series. The shift of PGD for aneuploidies from FISH to NGS‐based testing has further improved the pregnancy and implantation rates, leading also to a considerable reduction of spontaneous abortions. PGD is already moving towards the universal approaches, combining the testing for single‐gene and chromosomal disorders in a single test.
- 15 November 2016
- Published by Wiley
- p. 1-21
Preimplantation Diagnosis
Preimplantation diagnosis is testing for a causative gene before pregnancy, allowing the preselection of unaffected embryos before implantation into the uterus. It has currently become an alternative to prenatal diagnosis, providing an option for at‐risk couples to have unaffected children of their own without facing the risk of a pregnancy termination after prenatal diagnosis. Preimplantation diagnosis is also extended to late‐onset common disorders with genetic predisposition, such as cancer and heart disease, for which no preclinical diagnosis and effective preventive management exists. The other nontraditional application of preimplantation diagnosis is preimplantation HLA (human leukocyte antigen) typing to improve the access to the HLA‐identical stem cell transplantation, and this will contribute to the development of the cellular therapy for genetic and acquired disorders. However, the major current application of preimplantation genetic testing is detection and avoidance of aneuploid embryos, based on the currently used next‐generation technologies for 24‐chromosome aneuploidy testing, as the practical means in assisted reproduction technology (ART) to improve the in vitro fertilisation (IVF) effectiveness and general standards of ART. Key Concepts: PGD is no longer a research tool, but the established procedure in the genetic practices and ART. PGD not only avoids the birth of affected offspring but, most importantly, also ensures an unaffected pregnancy from the onset. Indications for PGD have currently been extended from the traditional ones, which are similar to prenatal diagnosis, to those that are not acceptable for prenatal diagnosis, such as late‐onset common disorders or identification of HLA match for stem cell transplantation. The majority of PGD is still performed for aneuploidy testing, as a tool to improve the efficiency of IVF. One of the most recent changes in PGD procedure in the last few years is shifting from blastomere biopsy to blastocyst sampling and vitrification, followed by the frozen transfer of tested embryos. The other important development in PGD is a shift of genetic testing from FISH testing for a few chromosomes most commonly involved in trisomies to the next‐generation technologies for 24‐chromosome aneuploidy testing. The number of different genetic conditions tested by PGD at the present time is over 400 and can be done not only for inherited conditions but also for those determined by de novo mutations. PGD for single‐gene disorders became extremely accurate and reliable, with as high as 99.5% accuracy in our PGD experience, which is the world's largest PGD series. The shift of PGD for aneuploidies from FISH to NGS‐based testing has further improved the pregnancy and implantation rates, leading also to a considerable reduction of spontaneous abortions. PGD is already moving towards the universal approaches, combining the testing for single‐gene and chromosomal disorders in a single test.